Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369268 | 0.80 | CYP1A2 (0.51) | NPSR1NPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL286492 | 0.78 | DAGLA (0.43) | DAGLANPSR1MAPK1NPC1TP53 | |
| SCHEMBL161081 | 0.78 | DAGLA (0.43) | DAGLANPSR1MAPK1NPC1TP53 | |
| SCHEMBL25139513 | 0.78 | — | — | |
| SCHEMBL4484701 | 0.77 | DAGLA (0.42) | DAGLANPSR1MAPK1NPC1TP53 | |
| SCHEMBL1196102 | 0.77 | DAGLA (0.42) | DAGLANPSR1MAPK1NPC1TP53 | |
| SCHEMBL25234479 | 0.77 | DAGLA (0.42) | DAGLANPSR1MAPK1TP53CYP1A2 | |
| SCHEMBL393999 | 0.77 | DAGLA (0.42) | DAGLANPSR1MAPK1CACNA1G | |
| SCHEMBL3425679 | 0.77 | DAGLA (0.39) | DAGLANPSR1NOTUMNQO2MAPK1 | |
| SCHEMBL780577 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-05-25 | — | — | US | disclosed |
| CN-115768772-A | Pyrano [4,3-b ] L indole derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4126881-A1 | PYRANO[4,3-B]L NDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| US-8829007-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-22 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2442809-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010148197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINB1, SERPINE1 | DAGLA 2225/4885NPSR1 2061/4885NOTUM 4317/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | DAGLA 2382/4885NPSR1 779/4885NOTUM 3617/4885 |
| US-20230157999-A1 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | DAGLA 2193/4885NPSR1 2087/4885NOTUM 4302/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | DAGLA 4006/4885NPSR1 1869/4885NOTUM 379/4885 |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | DAGLA 3939/4885NPSR1 2470/4885NOTUM 2176/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | DAGLA 4195/4885NPSR1 2023/4885NOTUM 2860/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | DAGLA 4472/4885NPSR1 1817/4885NOTUM 563/4885 |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | DAGLA 3939/4885NPSR1 2470/4885NOTUM 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.